Role of HGF/MET axis in resistance of lung cancer to contemporary management.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Translational Lung Cancer Research

• Publication date

  2012-09-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.3978/j.issn.2218-6751.2012.09.04PMID 25806180PMCID PMC4367559
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Wnt3 gene expression promotes tumor progression in non-small cell lung cancer.

  2012cited by this paper
• Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

  2012cited by this paper
• NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases

  2012cited by this paper
• cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes

  2012cited by this paper
• Combination of HDAC and topoisomerase inhibitors in small cell lung cancer

  2012cited by this paper
• Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.

  2012cited by this paper
• Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

  2012cited by this paper
• Targeting MET in cancer: rationale and progress

  2012cited by this paper
• Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.

  2012cited by this paper
• Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer

  2012cited by this paper
• Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.

  2012cited by this paper
• Targeting MET in cancer: rationale and progress

  2012cited by this paper
• Targeting the Met pathway in lung cancer

  2012cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• MET and phosphorylated MET as potential biomarkers in lung cancer.

  2011cited by this paper
• Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

  2011cited by this paper
• MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines

  2011cited by this paper
• Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.

  2011cited by this paper
• Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

  2011cited by this paper
• Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer.

  2011cited by this paper
• Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

  2011cited by this paper
• Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.

  2011influential reference
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• E7050: A dual c‐Met and VEGFR‐2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models

  2010cited by this paper
• Targeting the HGF/Met signalling pathway in cancer.

  2010cited by this paper
• Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.

  2010cited by this paper
• Concurrent chemoradiotherapy in non-small cell lung cancer.

  2010influential reference
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010influential reference
• Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

  2010cited by this paper
• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  2010cited by this paper
• Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

  2009cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

  2009influential reference
• MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality.

  2009cited by this paper
• Radiation-induced bystander signalling in cancer therapy

  2009cited by this paper
• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2009influential reference
• Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

  2009cited by this paper
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

  2009influential reference
• HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells.

  2008cited by this paper
• Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

  2008cited by this paper
• Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.

  2008cited by this paper
• Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

  2008cited by this paper
• Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.

  2008cited by this paper
• Inhibition of tumor-stromal interaction through HGF/Met signaling by valproic acid.

  2008cited by this paper
• Expression and mutational analysis of MET in human solid cancers

  2008cited by this paper
• Targeting the c-MET signaling pathway for cancer therapy.

  2008cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours

  2007cited by this paper
• Radiation-enhanced hepatocyte growth factor secretion in malignant glioma cell lines.

  2007cited by this paper
• A positive feedback loop between hepatocyte growth factor receptor and β-catenin sustains colorectal cancer cell invasive growth

  2007cited by this paper
• c-Met is essential for wound healing in the skin

  2007cited by this paper
• Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases.

  2007cited by this paper
• The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours

  2007cited by this paper
• Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.

  2006influential reference
• Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

  2006cited by this paper
• Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

  2006cited by this paper
• Effect of c-Met Expression on Survival in Head and Neck Squamous Cell Carcinoma

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006influential reference
• Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells

  2006cited by this paper
• Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.

  2006cited by this paper
• Regulatory role of c-Met in insulin-like growth factor-I receptor–mediated migration and invasion of human pancreatic carcinoma cells

  2006cited by this paper
• ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.

  2005cited by this paper
• Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation.

  2005cited by this paper
• Targeting the c-Met Pathway Potentiates Glioblastoma Responses to γ-Radiation

  2005cited by this paper
• Sublethal irradiation promotes invasiveness of neuroblastoma cells.

  2005cited by this paper
• Inhibition of apoptosis‐inducing factor translocation is involved in protective effects of hepatocyte growth factor against excitotoxic cell death in cultured hippocampal neurons

  2005cited by this paper
• Phosphatidylinositide 3-kinase/AKT in radiation responses.

  2004cited by this paper
• Met provides essential signals for liver regeneration.

  2004cited by this paper
• Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

  2004cited by this paper
• Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas

  2004cited by this paper
• Radiation oncology: a century of achievements

  2004cited by this paper
• Clinical studies of irinotecan alone and in combination with cisplatin

  2004cited by this paper
• Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer.

  2004influential reference
• Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.

  2004cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004cited by this paper
• Met, metastasis, motility and more

  2003influential reference
• Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.

  2003cited by this paper
• Radiation stimulates HGF receptor/c‐Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells

  2003cited by this paper
• Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription

  2003cited by this paper
• Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor

  2003cited by this paper
• Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.

  2003cited by this paper
• Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation

  2003cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor

  2002cited by this paper
• Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

  2002cited by this paper
• Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial

  2002cited by this paper
• Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer.

  2002cited by this paper
• Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria.

  2002cited by this paper
• Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.

  2002cited by this paper
• Regulation of the Mitogen-activated Protein Kinase Signaling Pathway by SHP2*

  2002cited by this paper
• Src Homology 2-containing Inositol 5-Phosphatase 1 Binds to the Multifunctional Docking Site of c-Met and Potentiates Hepatocyte Growth Factor-induced Branching Tubulogenesis*

  2001cited by this paper
• c‐erbB‐2 Expression in small‐cell lung cancer is associated with poor prognosis

  2001cited by this paper
• Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways.

  2001cited by this paper
• Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.

  2001cited by this paper
• Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.

  2001cited by this paper

• A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models

  2025cites this paper
• Study Polymorphism of MET Gene in Cancer Iraqi Patients (AML)

  2025cites this paper
• Mesenchymal stem cells promote erlotinib resistance in non-small cell lung cancer through the HGF-AKT/ERK1/2-OPN pathway.

  2025cites this paper
• Cigarette smoke extract induces malignant transformation and DNA damage via c-MET phosphorylation in human bronchial epithelial cells.

  2024cites this paper
• Targeting cytokine and chemokine signaling pathways for cancer therapy

  2024cites this paper
• Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road

  2024cites this paper
• A patient-specific lung cancer assembloid model with heterogeneous tumor microenvironments

  2024cites this paper
• Hexane Fraction of Adenophora triphylla var. japonica Root Extract Inhibits Angiogenesis and Endothelial Cell-Induced Erlotinib Resistance in Lung Cancer Cells

  2024cites this paper
• Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

  2024cites this paper
• Antitumor Activity of a Bispecific Chimera Targeting EGFR and Met in Gefitinib‐Resistant Non‐Small Cell Lung Cancer

  2024cites this paper
• Comparison of the effects of crizotinib as monotherapy and as combination therapy with butyric acid on different breast cancer cells.

  2024cites this paper
• Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells

  2023cites this paper
• The role of α7-nAChR-mediated PI3K/AKT pathway in lung cancer induced by nicotine.

  2023cites this paper
• Molecular pathology of non‐small cell carcinoma

  2023cites this paper
• Diverse regulated cell death modes predict the immune microenvironment and drug sensitivity in lung adenocarcinoma

  2023cites this paper
• Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancer

  2023cites this paper
• NTRK3 gene fusion in an adult ganglioglioma: illustrative case

  2022cites this paper
• Targeting GSTP1-dependent ferroptosis in lung cancer radiotherapy: Existing evidence and future directions

  2022cites this paper
• MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer

  2022cites this paper
• Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge

  2022cites this paper
• Network-based toxicogenomic approach to explore oral benzo(a)pyrene exposure effect on respiratory system

  2022cites this paper
• Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation

  2022cites this paper
• The Role of HGF/MET Signaling in Metastatic Uveal Melanoma

  2021influential citation
• Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway

  2021cites this paper
• Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression

  2020cites this paper
• Knockdown GTSE1 enhances radiosensitivity in non–small‐cell lung cancer through DNA damage repair pathway

  2020cites this paper
• Increase in Toxicity of Anticancer Drugs by PMTPV, a Claudin-1-Binding Peptide, Mediated via Down-Regulation of Claudin-1 in Human Lung Adenocarcinoma A549 Cells

  2020influential citation
• Understanding the Evolutionary Games in NSCLC Microenvironment

  2020cites this paper
• Molecular changes in EGFR downstream signalling and intracellular calcium changes associated with the cisplatin-resistant phenotype of lung cancer cells

  2020cites this paper
• Overcoming multiple drug resistance in lung cancer using siRNA targeted therapy.

  2019cites this paper
• Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation

  2019cites this paper
• Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts

  2019cites this paper
• ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma.

  2019cites this paper
• MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM

  2019cites this paper
• Preclinical Evaluation Of Curcumin And Its Meriva Formulation For Non-Small Cell Lung Cancer Chemoprevention

  2019cites this paper
• Gene silencing strategies in cancer therapy: An update for drug resistance.

  2018cites this paper
• Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

  2018cites this paper
• miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway

  2018cites this paper
• Untying the gordion knot of targeting MET in cancer.

  2018cites this paper
• A Systems Chemical Biology Approach for Dissecting Differential Molecular Mechanisms of Action of Clinical Kinase Inhibitors in Lung Cancer

  2018cites this paper
• Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents

  2017cites this paper
• Determination of 16 serum angiogenic factors in stage I non-small cell lung cancer using a bead-based multiplex immunoassay.

  2017cites this paper
• Expression of HGF, MET and mutated EGFR in EGFR mutated lung adenocarcinoma and their clinical significance

  2017influential citation
• Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?

  2017cites this paper
• Oncogenomics of c-Myc transgenic mice reveal novel regulators of extracellular signaling, angiogenesis and invasion with clinical significance for human lung adenocarcinoma

  2017cites this paper
• Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts.

  2017cites this paper
• Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer

  2017cites this paper
• MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway

  2016cites this paper
• Preclinical evaluation of Meriva (a formulation of curcumin) as a putative agent for chemoprevention of lung cancer

  2016cites this paper
• Gabriella. Synergistic activation upon MET and ALK coamplification sustains targeted therapy in sarcomatoid Carcinoma, a deadly subtype of lung

  2016cites this paper
• Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer

  2016cites this paper
• Knockdown of Long Noncoding RNA uc.338 by siRNA Inhibits Cellular Migration and Invasion in Human Lung Cancer Cells

  2016cites this paper
• Metabolic response of lung cancer cells to radiation in a paper-based 3D cell culture system.

  2016cites this paper
• Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma

  2016cites this paper
• Evaluation of c-MET as a predictive marker for response to sorafenib in advanced hepatocellular carcinoma submitted by

  2016cites this paper
• Effective Combined Treatment with Aqueous Extract of Taxuschinensis var.mairei (AETC) and Gefitinib in Inhibiting Non-SmallCell Lung Cancer PC9, PC9/R Cell Lines In Vitro and In Vivo

  2016cites this paper
• A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells

  2015cites this paper